z-logo
open-access-imgOpen Access
Clinical, functional and genetic characterization of 16 patients suffering from chronic granulomatous disease variants – identification of 11 novel mutations in CYBB
Author(s) -
Mollin M.,
Beaumel S.,
Vigne B.,
Brault J.,
RouxBuisson N.,
Rendu J.,
Barlogis V.,
Catho G.,
Dumeril C.,
Fouyssac F.,
Monnier D.,
Gandemer V.,
Revest M.,
Brion J.P.,
BostBru C.,
Jeziorski E.,
Eitenschenck L.,
Jarrasse C.,
Drillon Haus S.,
HouachéeChardin M.,
Hancart M.,
Michel G.,
Bertrand Y.,
Plantaz D.,
Kelecic J.,
Traberg R.,
Kainulainen L.,
Fauré J.,
Fieschi F.,
Stasia M. J.
Publication year - 2021
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/cei.13520
Subject(s) - chronic granulomatous disease , missense mutation , nadph oxidase , exon , mutation , genetics , microbiology and biotechnology , nox1 , biology , gene , reactive oxygen species
Sixteen CGD cases were clinically, functionally and genetically characterized and classified as suffering from different variant forms (X91 0 , X91 − or X91 + ) according to NOX2 expression and NADPH oxidase activity in their neutrophils. The pathological impact of each mutation of the new and extremely rare double missense mutation Thr208Arg‐Thr503Ile in CYBB was investigated using stable transfection in the NOX2 knock‐out PLB‐985 cell line. Low NADPH oxidase activity found in X91 − ‐CGD patients correlates with mild clinical forms, whereas X91 0 ‐CGD and X91 + ‐CGD cases remain the most clinically severes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom